TerminatedPhase 2NCT00262925
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Peter Wiernik, M.DMontefiore Medical Center
- Intervention
- alemtuzumab(biological)
- Enrollment
- 12 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2013
Study locations (30)
- Rush - Copley Medical Center, Aurora, Illinois, United States
- Mercy Hospital and Medical Center, Chicago, Illinois, United States
- Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States
- Edward H Kaplan MD and Associates, Skokie, Illinois, United States
- Carle Clinic-Urbana Main, Urbana, Illinois, United States
- Saint Anthony Memorial Health Center, Michigan City, Indiana, United States
- Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States
- Mercy Medical Center-Sioux City, Sioux City, Iowa, United States
- Saint Luke's Regional Medical Center, Sioux City, Iowa, United States
- Cancer Center of Kansas - Chanute, Chanute, Kansas, United States
- Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States
- Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States
- Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States
- Cancer Center of Kansas-Independence, Independence, Kansas, United States
- Cancer Center of Kansas-Kingman, Kingman, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00262925 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University